<SEC-DOCUMENT>0001193125-25-233681.txt : 20251007
<SEC-HEADER>0001193125-25-233681.hdr.sgml : 20251007
<ACCEPTANCE-DATETIME>20251007172442
ACCESSION NUMBER:		0001193125-25-233681
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251007
DATE AS OF CHANGE:		20251007

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279773
		FILM NUMBER:		251380682

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d91027d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-279773 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
December&nbsp;2, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>1,770,000 American Depositary Shares representing </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>885,000,000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary
Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g91027g1007001721111.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December&nbsp;2, 2024 (the
&#8220;Prospectus&#8221;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on October 7, 2025 (the &#8220;October 7, 2025 Form <FONT STYLE="white-space:nowrap">6-K&#8221;).</FONT> Accordingly, we have attached
the October 7, 2025 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and supplements
the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction
with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;KZIA.&#8221; On October 7, 2025, the last reported sale price
of the ADSs on Nasdaq was $7.14 per ADS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page
9 of the Prospectus and the &#8220;Risk Factors&#8221; in &#8220;Item 3. Key <FONT STYLE="white-space:nowrap">Information-D.</FONT> Risk Factors&#8221; of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is
incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is October 7, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#8217;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 7, 2025, Kazia Therapeutics Limited (the &#8220;Company&#8221; or &#8220;Kazia&#8221;) announced an exclusive
collaboration and <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement (the &#8220;Agreement&#8221;) with QIMR Berghofer for a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT
STYLE="white-space:nowrap">PD-L1</FONT> degrader program. The lead optimized compound, NDL2, is an advanced <FONT STYLE="white-space:nowrap">PD-L1</FONT> protein degrader currently in development and represents a new and innovative frontier of
cancer immunotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The program will initially target advanced breast cancer and <FONT STYLE="white-space:nowrap">non-small</FONT> cell
lung cancer (NSCLC), where <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> immunotherapies are widely used but resistance remains common. <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies are
expected to commence within six months, with a goal of initiating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> studies within approximately 15 months. Kazia also intends to explore synergistic
opportunities to combine NDL2 with its existing pipeline assets, including paxalisib (a <FONT STYLE="white-space:nowrap">pan-PI3K/mTOR</FONT> inhibitor) and EVT801 (a selective VEGFR3 inhibitor), given their complementary mechanisms of action in
modulating the tumor microenvironment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement, Kazia will make a
<FONT STYLE="white-space:nowrap">one-time</FONT> payment of approximately $1.39&nbsp;million 15 business days after signing, is responsible for all development costs.&nbsp;Kazia will receive a percentage of commercialization revenue ranging from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-to-high</FONT></FONT> double digits depending on the stage of development, which includes any <FONT STYLE="white-space:nowrap">out-licensing</FONT> payments received from third parties.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 7, 2025, Kazia issued a press release titled &#8220;Kazia Therapeutics Announces Collaboration and <FONT
STYLE="white-space:nowrap">In-Licensing</FONT> Agreement for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT> <FONT STYLE="white-space:nowrap">PD-L1</FONT> Protein Degrader Program.&#8221; A copy of this
release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the
information contained herein, including Exhibit 99.1, except for the quote of Dr.&nbsp;John Friend, Chief Executive Officer of the Company, and the quote of Professor Sudha Rao, Principal Investigator at QIMR Berghofer, contained in Exhibit 99.1,
into the Company&#8217;s registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-281937).</FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;future,&#8221; &#8220;forward,&#8221;
&#8220;anticipate,&#8221; or other similar words. Any statement describing Kazia&#8217;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking
statements, including, but not limited to, statements regarding: the potential benefits of NDL2 and the plans and goals of developing NDL2 formulation, the anticipated development pathways and combinations of NDL2, the anticipated payments under the
Agreement, the timing for results and data related to Kazia&#8217;s clinical and preclinical trials, Kazia&#8217;s strategy and plans with respect to its paxalisib program, the potential benefits of paxalisib as an investigational PI3K/mTOR
inhibitor, timing for any regulatory submissions or discussions with regulatory agencies and the potential market opportunity for paxalisib. Such statements are based on Kazia&#8217;s current expectations and projections about future events and
future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with
clinical and preclinical trials and product development, including the risk that interim or early data may not be consistent with final data, risks related to regulatory approvals, risks related to the impact of global economic conditions, and risks
related to Kazia&#8217;s ability to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia&#8217;s Annual Report, filed on
Form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated October 7, 2025</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited (Registrant)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 7, 2025</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, Australia &#8211; October&nbsp;7, 2025 &#8211; Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced
an exclusive collaboration and in-licensing agreement (the &#8220;Agreement&#8221;) with QIMR Berghofer for a first-in-class PD-L1 degrader program. The lead optimized compound, NDL2, is an advanced PD-L1 protein degrader currently in development
and represents a new and innovative frontier of cancer immunotherapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About PD-L1 Degradation and NDL2</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cancer cells frequently express PD-L1 protein to evade immune attack. When PD-L1 on a tumor cell surface binds to PD-1 on a T cell, the T cell becomes
inactivated and loses its ability to destroy the cancer. Traditional checkpoint inhibitors such as pembrolizumab (Keytruda<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) and nivolumab
(Opdivo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) use monoclonal antibodies to block this surface interaction, helping to restore T-cell activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, research has shown that PD-L1 also exists in post-translationally modified forms that are enriched in patients who fail or relapse on checkpoint
inhibitor therapy. These modified proteins are found on the cell surface as well as in the cytoplasm and nucleus, where they contribute to resistance and tumor progression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NDL2 takes a fundamentally different approach. This novel bicyclic peptide degrader, discovered and developed by Professor Sudha Rao, is designed to
specifically recognize and degrade these resistant, post-translationally modified forms of PD-L1. By binding PD-L1 and recruiting the cell&#8217;s natural protein disposal machinery, NDL2 drives the breakdown and clearance of the modified PD-L1
across all cellular compartments. Targeting these resistant PD-L1 pools that antibody therapies cannot reach offers the potential to overcome immunotherapy resistance and restore durable immune activity against tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe this comprehensive degradation strategy has the potential to offer two major clinical advantages: (1) Overcoming resistance in both primary
non-responders and patients who relapse on antibody therapies, and (2) Providing durable immune reactivation by restoring cytotoxic T-cell function and reducing T-cell exhaustion in the tumor microenvironment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NDL2 Preclinical Evidence</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preclinical models of
aggressive triple-negative breast cancer (TNBC), NDL2 monotherapy, as well as in combination with anti-PD-1 therapies, achieved significant tumor growth reduction. Importantly, treated tumors showed reduced T-cell exhaustion and enhanced immune
activity, consistent with NDL2&#8217;s dual mechanism of action. Across the preclinical work to date, no toxicity has been observed. Professor Rao and QIMR Berghofer are working in parallel with a number of world-leading oncology peptide
manufacturers to optimize the stability, potency, pharmacokinetics and pharmacodynamics of the NDL2 formulation. <B> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Development Pathway and Combinations </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The program will initially target advanced breast cancer and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), where <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> immunotherapies are widely used but resistance remains common. <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies are expected to commence within six
months, with a goal of initiating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> studies within approximately 15 months. Kazia also intends to explore synergistic opportunities to combine NDL2 with its
existing pipeline assets, including paxalisib (a <FONT STYLE="white-space:nowrap">pan-PI3K/mTOR</FONT> inhibitor) and EVT801 (a selective VEGFR3 inhibitor), given their complementary mechanisms of action in modulating the tumor microenvironment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;John Friend, Chief Executive Officer of Kazia Therapeutics, commented: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;This Agreement positions Kazia at the forefront of next-generation immuno-oncology. NDL2 is a truly <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> asset, representing an advanced <FONT STYLE="white-space:nowrap">PD-L1</FONT> degrader, and what we believe one of the most exciting innovations in targeted protein degradation. This program
complements our existing pipeline, with clear opportunities for synergy with other immunotherapies as well as paxalisib and EVT801, and we are positioned to rapidly advance it toward the clinic.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Professor Sudha Rao, Principal Investigator at QIMR Berghofer and inventor of the <FONT STYLE="white-space:nowrap">PD-L1</FONT> degrader program, added: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;NDL2 has the potential to redefine immunotherapy by targeting all functional pools of <FONT STYLE="white-space:nowrap">PD-L1</FONT> protein, not just
the surface expression blocked by current antibodies. By eliminating <FONT STYLE="white-space:nowrap">PD-L1</FONT> throughout the cell, we can address resistance and other pathways that drive aggressive cancers like TNBC and NSCLC. We are thrilled
to partner with Kazia to potentially translate this novel science into a transformative therapy for patients.&#8221; <B> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration and
Licensing Terms</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the collaboration Agreement, Kazia will make a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of
approximately $1.39&nbsp;million 15 business days after signing and is responsible for all development costs. Kazia will share a percentage of commercialization revenue, which includes any <FONT STYLE="white-space:nowrap">out-licensing</FONT>
payments received from third parties. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For investor and media, please contact Alex Star, Managing Director LifeSci Advisors LLC,
Astarr@lifesciadvisors.com, +1-201-786-8795. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an
investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this
disease. A completed Phase 2/3 study in glioblastoma </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">(GBM-Agile)</FONT> was reported in 2024 and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval.
Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib
was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the
treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic
pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical
data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research
Symposium in September 2024. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx. <B> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking
Statements </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as
&#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;future,&#8221; &#8220;forward,&#8221; &#8220;anticipate,&#8221; or other similar words. Any statement describing Kazia&#8217;s future plans, strategies, intentions, expectations,
objectives, goals or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, statements regarding: the potential benefits of NDL2 and the plans and goals of developing NDL2
formulation, the anticipated development pathways and combinations of NDL2, the anticipated payments under the Agreement, the timing for results and data related to Kazia&#8217;s clinical and preclinical trials, Kazia&#8217;s strategy and plans with
respect to its paxalisib program, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies and the potential market opportunity for paxalisib. Such
statements are based on Kazia&#8217;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from
those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical and preclinical trials and product development, including the risk that interim or early data may not be consistent with final data,
risks related to regulatory approvals, risks related to the impact of global economic conditions, and risks related to Kazia&#8217;s ability to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and
standards. These and other risks and uncertainties are described more fully in Kazia&#8217;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the United States Securities and
Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance
on these forward-looking statements, which apply only as of the date of this announcement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g91027g1007001721111.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g91027g1007001721111.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ -D# 2(  A$! Q$!_\0
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GR$8S6RO>FA1GVIPQVI,J"LA:7%)FC-(H,"EI,T9H 6DHS24 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
